Rubella (German Measles): Virology, Congenital Rubella Syndrome, and Laboratory Diagnosis

In the mother, rubella is forgettable: a light fever, a rash that fades in three days, some aching joints. In the fetus, the same virus in the same weeks can cause deafness, blindness, and heart defects that last a lifetime. That gap between a trivial maternal illness and a devastating fetal one is the whole reason rubella matters in obstetrics, and it is why the strategy has always been to protect the mother in order to protect the fetus.

The 1964 to 1965 pandemic made the point at scale: an estimated 50,000 pregnancies in the United States were affected, with miscarriages, stillbirths, and babies born with congenital rubella syndrome. A vaccine followed within a decade, and with it, rubella and congenital rubella syndrome disappeared from many countries that vaccinate their childbearing-age population. Where that immunity is missing, the disease returns.

What rubella is

Rubella, or German measles, is a mild, contagious viral illness whose name comes from the Latin for "little red." It was once mistaken for a variant of measles or scarlet fever and called "third disease." The important clinical fact is the split between its two settings: postnatal infection is benign, while first-trimester intrauterine infection is teratogenic.

Rubella virus is a single-stranded, positive-sense RNA virus, enveloped, with icosahedral symmetry. It is the sole human pathogen in the genus Rubivirus, family Matonaviridae (reclassified from Togaviridae in 2018, on the grounds that rubella differs from the alphaviruses in its transmission, virion structure, and genetics, and is not spread by arthropods). Many older textbooks still list it under Togaviridae, so you may meet either name in an exam; the current family is Matonaviridae. Humans are the only known host and reservoir, which is what makes rubella eliminable by vaccination.

Transmission

Rubella spreads person to person by respiratory droplets and by direct contact with nasal or throat secretions; freshly contaminated articles can transmit indirectly. A patient is contagious from about one week before the rash to one week after it appears.

One transmission fact carries disproportionate weight for infection control. Infants with congenital rubella syndrome shed large quantities of virus in their pharyngeal secretions and urine, and they can continue shedding for up to a year after birth. A congenitally infected newborn is therefore a reservoir, and a hazard to non-immune pregnant contacts, long after delivery.

Clinical features of postnatal rubella

The incubation period averages 14 to 18 days, with a range of about 12 to 23 days. Roughly half of infections are subclinical, which matters because an unrecognized infection in a pregnant woman still reaches the fetus.

In children, the illness is a rash that begins on the face and spreads down the body, with a low-grade fever, lasting two or three days. Older children and adults often have a prodrome of malaise and low fever with tender lymphadenopathy, classically postauricular, suboccipital, and posterior cervical, appearing before the rash. Arthralgia and arthritis are common in young women. The disease is self-limiting and needs only supportive care.

Rubella as a viral exanthem

Rubella is one of the classic childhood exanthems, and in the skin-infection setting the task is usually to tell it apart from the other rashes it resembles, above all measles.

The rubella rash is a pink-to-red maculopapular eruption that begins on the face and spreads downward to the trunk and limbs over about 24 hours, then fades in the same head-to-foot order by roughly the third day. It is finer and paler than the measles rash, and unlike measles the individual spots tend not to coalesce into large blotches. The rash is often the first sign noticed in children, whereas in older children and adults a prodrome of low fever and tender lymphadenopathy precedes it.

Two features help identify rubella clinically:

Lymphadenopathy. Tender postauricular, suboccipital, and posterior cervical nodes are characteristic of rubella and often precede the rash. This lymphadenopathy is a more reliable rubella clue than the rash itself.

No Koplik spots, no measles prodrome. Unlike measles, rubella has no Koplik spots and no preceding cough, coryza, and conjunctivitis. A descending maculopapular rash with tender postauricular nodes and none of those measles features is rubella. The fuller side-by-side of the childhood exanthems is covered separately, as optional further reading, on the measles page.

Forschheimer spots, small red spots on the soft palate, may appear in rubella, but they are not specific and are also seen in other exanthems, so they do not carry the diagnostic weight that Koplik spots do for measles.

The rash and its differential matter for one reason beyond the child in front of you: recognizing rubella means recognizing a transmission risk to any non-immune pregnant contact. The diagnosis is confirmed serologically, not by the appearance of the rash, because several exanthems look alike and rubella is too consequential in pregnancy to diagnose on morphology alone.

Rubella in pregnancy and congenital rubella syndrome

When a non-immune woman acquires rubella during pregnancy, the virus can cross the placenta and cause fetal death, miscarriage, or a cluster of birth defects called congenital rubella syndrome (CRS). Worldwide, over 100,000 babies are born with CRS each year, and the risk concentrates in populations where women of childbearing age are not immune.

Two principles govern fetal risk, and both belong in memory:

Timing determines risk and severity. First-trimester infection carries by far the highest risk of transmission causing severe defects, because organogenesis is under way. Infection later in pregnancy is progressively less dangerous. This front-loaded risk is why the question a clinician asks is always how many weeks, and why rubella is the archetype of a severe-early congenital infection.

The classic triad is worth carrying as a unit: sensorineural deafness (the single most common defect), cataracts and other eye lesions, and congenital heart disease, most characteristically patent ductus arteriosus. Beyond the triad, CRS can include microcephaly, intellectual disability, and a "blueberry muffin" rash from dermal extramedullary hematopoiesis. Deafness may be the only manifestation when infection occurs toward the end of the first trimester.

Immunity from infection or vaccination before pregnancy protects the fetus, because the mother carries protective antibody before conception. The danger is a first, primary infection during pregnancy in a non-immune woman. This is the same primary-infection principle that runs through the other congenital infections, and it is what a TORCH panel is designed to detect.

Reading such a panel across several organisms at once is covered separately, as optional further reading, in the article on the TORCH panel test.

Laboratory diagnosis

Rubella is diagnosed serologically. The antibody kinetics are the key to interpretation: both IgG and IgM appear about 14 to 18 days after infection, and rubella IgM wanes quickly, usually becoming undetectable within about two months. That fast decay is clinically useful, because a positive rubella IgM points to genuinely recent infection rather than an old one, in contrast to some other congenital pathogens whose IgM can persist for many months.

The tests in routine use are: detection of IgM, which indicates recent infection; detection of IgG, which indicates immunity, whether from past infection or vaccination; and a four-fold or greater rise in antibody titer between acute and convalescent sera, which confirms acute infection.

Viral culture is possible but slow and reserved for reference settings. In a newborn, the interpretation follows the general congenital-serology rule: IgG may be passively transferred maternal antibody, whereas IgM, which does not cross the placenta, indicates true fetal infection. For prenatal confirmation, rubella RNA can be detected by molecular methods.

Prevention

Prevention is the point of the whole rubella program. The vaccine is a live attenuated virus, given as part of MMR, and it works by making women immune before they conceive. Because it is a live vaccine, it is contraindicated during pregnancy, and pregnancy should be avoided for about a month after vaccination. Susceptible women identified during pregnancy are therefore vaccinated after delivery, not during. The strategy is deliberately indirect: you vaccinate the population to raise herd immunity and protect future pregnancies, because there is no treatment that undoes fetal infection once it has occurred.

How to Remember

Little red, big trouble, but only for the fetus. The name means "little red," and the maternal illness is genuinely little: three days of rash and mild fever. The whole clinical weight falls on the fetus. Holding those two facts together is the core of the topic.

The CRS triad: hear, see, beat. Deafness (hear), cataracts (see), and congenital heart disease, classically patent ductus arteriosus (beat). Sensorineural deafness is the commonest and may be the only sign in later first-trimester infection.

Rubella descends and clears fast. The rash starts on the face and moves down, but stays fine, pale, and non-confluent, and is gone by about day three, with tender postauricular nodes and no Koplik spots. Measles, by contrast, is louder and blotchier, with Koplik spots first.

Vaccinate before, never during. The vaccine is live, so it is given before pregnancy and withheld during it. The goal is immunity at conception, because after the virus reaches the fetus there is nothing to give that reverses the damage.

Rubella IgM tells the truth quickly. Because rubella IgM disappears within about two months, a positive result means recent infection. This is a useful contrast with toxoplasmosis, where a positive IgM can linger and needs an avidity test to time it.

Key exam facts in one table

Where Students Get Confused

Rubella and rubeola are the same thing. They are not. Rubella (German measles, family Matonaviridae) and rubeola (measles, a paramyxovirus) are different viruses with different families, different clinical courses, and different complications. The similar names are a historical accident. Rubella is milder in the patient but teratogenic in pregnancy; measles is more severe in the patient and not a classic congenital teratogen in the same way.

Rubella and measles rashes are hard to tell apart, so you cannot distinguish them clinically. You often can. Both descend from the face, but rubella is finer and non-confluent, clears by about day three, comes with tender postauricular and suboccipital nodes, and lacks Koplik spots and the measles prodrome of cough, coryza, and conjunctivitis. Confirmation is still serological, because the stakes in pregnancy are too high to rely on the rash.

If the mother's illness was trivial, the fetus is fine. No. About half of maternal infections are subclinical, and a mild or unnoticed maternal illness in the first trimester can still cause severe CRS. The severity of the maternal illness does not predict the fetal outcome; the timing of infection does.

The rubella vaccine can be given during pregnancy to protect the fetus. It cannot. It is a live vaccine and is contraindicated in pregnancy. Protection has to be in place before conception. A susceptible pregnant woman is vaccinated after she delivers.

A positive IgG in a newborn means the baby is infected. Not on its own. IgG crosses the placenta, so a newborn's IgG may simply be the mother's antibody passively transferred. Maternal IgM does not cross the placenta, so a positive rubella IgM in the newborn must be the infant's own and indicates true congenital infection.

Congenital rubella risk is the same throughout pregnancy. It is strongly front-loaded. First-trimester infection carries the highest risk of severe defects; risk falls as pregnancy advances. This timing dependence is the single most testable fact about CRS.

References

• Riedel S, Hobden JA, Miller S, et al. Jawetz, Melnick & Adelberg's Medical Microbiology. 28th ed. New York: McGraw Hill; 2019.
• Mankertz A, et al. ICTV Virus Taxonomy Profile: Matonaviridae. J Gen Virol. 2022;103(11):001817. https://doi.org/10.1099/jgv.0.001817
• Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet. 2015;385(9984):2297–2307. https://doi.org/10.1016/S0140-6736(14)60539-0
• World Health Organization. Rubella fact sheet. Geneva: WHO. https://www.who.int/news-room/fact-sheets/detail/rubella